Skip to content

Adding Zinc to Blood Pressure Medications: Effects on Blood Pressure and Well-Being

Efficacy and Safety of Zinc Supplementation on Blood pressure and Quality of life in patients receiving Telmisartan and Hydrochlorothiazide combination: A randomised open label study - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/09/094586
Enrollment
142
Registered
2025-09-11
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: Telmisartan plus hydrochlorothiazide with zinc sulphate: Telmisartan 40 mg and Hydrochlorothiazide 12.5 mg once daily in the morning at for three month + Zinc 20 mg elemental zinc once

Sponsors

Mini Sharma
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged between 18 to 65 years Newly diagnosed case of Grade 1 primary hypertension Systolic BP 140 to 159 mm of Hg DBP 90 to 99 mm Hg Patient is willing to come for follow up till 12 weeks Patient is willing to give informed written consent

Exclusion criteria

Exclusion criteria: Patient suffering with Stage 2 or stage 3 primary hypertension Patient suffering with diagnosed secondary hypertension Patients have contraindication or allergic to Zinc, Telmisartan or Hydrochlorothiazide Patient giving history of taking mineral supplement in last 3 month before enrolment Patient having history of ischemic heart disease, stroke, congestive heart failure, clinically significant arrhythmia or conduction disorders, diagnosed end stage renal disease, abnormal liver function or critically ill patient Systolic Blood pressure difference in both arms more than 10 mmHg Pregnant female Lactating mother

Design outcomes

Primary

MeasureTime frame
1. Change in systolic blood pressure (SBP) from baseline to 12 weeks. 2. Change in diastolic blood pressure (DBP) from baseline to 12 weeks.Timepoint: All the patients will be asked to come for follow-up at 4, and 8- and 12-weeks post-treatment and patients will be evaluated thoroughly for the efficacy, and safety parameters at each visit.

Secondary

MeasureTime frame
1) Change in quality of life from baseline to 12 weeks. 2) Incidence, type, causality, preventability and severity of adverse effects in both the group.Timepoint: 1)Quality of life will be evaluated at baseline and 12th week. 2)Any adverse effect will be evaluated and reported during study duration from baseline till 12 weeks.

Countries

India

Contacts

Public ContactMini Sharma
drshubhasinghal@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026